Document Detail


Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.
MedLine Citation:
PMID:  21047924     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVE: Synthetic glucagon-like peptide-1 (7-36)amide (GLP-1) lowers postprandial (pp) glycemia by stimulating insulin and inhibiting glucagon release and delaying gastric emptying (GE). However, the biological effects of the endogenous peptide and their relative contributions to pp glycemia remain to be defined in detail. Using the specific GLP-1 receptor antagonist exendin(9-39)amide [Ex(9-39)], we studied the exact impact of GLP-1 after an oral meal in humans.
RESEARCH DESIGN AND METHODS: After a 50-min basal period, 12 healthy subjects ingested a 412-kcal mixed semisolid meal containing 30 g oatmeal, labeled with 99mTc-Sn-colloid. GE was measured by high-resolution scintigraphy until 210 min after meal ingestion. In random order, saline or Ex(9-39) at 900 pmol/kg·min was infused iv. Additionally, in six subjects gastric motility was measured by antroduodenal manometry and a gastric barostat in parallel.
RESULTS: Ex(9-39) increased pp blood glucose excursions during the first 60 min after the meal (43.9 ± 5.4 vs. 35.9 ± 3.6 mg/dl, P = 0.008; pp peak glucose 154.0 ± 5.5 vs.141.0 ± 4.7 mg/dl, P = 0.009). Insulin increased slightly with Ex(9-39), whereas the insulin to glucose ratio was unchanged. pp glucagon was significantly increased with Ex(9-39) (7.5 ± 2.4 vs. 3.2 ± 2.1 pg/ml, P = 0.024). GE and accordingly gastric motility did not change with Ex(9-39). Multiple linear regression analysis revealed only changes of pp glucagon to be significantly associated with increased pp glycemia under Ex(9-39) (R = 0.678, P = 0.015).
CONCLUSIONS: Released after an oral meal, GLP-1 lowers pp glycemia. In this study, the inhibition of glucagon release was a major determinant of the acute GLP-1 action in healthy subjects. In contrast, gastric emptying was not changed by GLP-1 receptor antagonism.
Authors:
Mathias Nicolaus; Julia Brödl; Rainer Linke; Hans-Juergen Woerle; Burkhard Göke; Jörg Schirra
Related Documents :
10823914 - Enhanced insulin secretion and improved glucose tolerance in mice lacking cd26.
20844284 - Gip: no longer the neglected incretin twin?
11061504 - Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and i...
3135584 - 'entero-insular axis' and surgical trauma.
12542724 - Rosiglitazone (ppargamma-agonist) attenuates atherogenesis with no effect on hyperglyca...
18925914 - Macular thickness and systemic markers for diabetes in individuals with no or mild diab...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-03
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  96     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  229-36     Citation Subset:  AIM; IM    
Affiliation:
Department of Internal Medicine II, Ludwig-Maximilians University, Munich, Germany. mathias.nicolaus@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecula...
Next Document:  Identification of adipocyte genes regulated by caloric intake.